MEDIPOST obtained a patent for its technique used for developing a stem cell drug pipeline (3 types).

MEDIPOST obtained a patent in the US for ‘Treatment for damage arthritis using TSP-2 expression by mesenchymal stem cells from cord blood’ used in developing its ‘CARTISTEM^®’ for treating knee cartilage loss.

This patented technology uses protein secreted from mesenchymal stem cells in cord blood to regenerate cartilage tissues and treat infections.

MEDIPOST has also previously obtained patents for its drugs to treat Alzheimer’s disease and lung diseases in the US.